使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning and thank you for standing by. Welcome to Abbott's first quarter 2026 earnings conference call. (Operator Instructions). This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.
各位早安,感謝您稍候。歡迎參加雅培(Abbott)2026 年第一季財報電話會議。(接線員指示)。本次電話會議由雅培錄音。除問答環節中任何與會者提出的問題外,整場會議(包括問答環節)均為雅培享有之具重大性之著作權內容。未經雅培明確書面許可,不得錄音或轉播。現在我想介紹投資人關係副總裁 Mike Comilla 先生。
Mike Comilla - Vice President, Investor Relations
Mike Comilla - Vice President, Investor Relations
Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks.
各位早安,感謝您加入我們。今天與我一同出席的有董事長兼執行長 Robert Ford,以及財務執行副總裁兼財務長 Phil Boudreau。Robert 與 Phil 將先發表開場談話。
Following their comments, we'll take your questions. Before we get started, statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2026.
在他們的談話之後,我們將開放提問。在開始之前,今天所作之陳述可能構成《1995 年私人證券訴訟改革法》(Private Securities Litigation Reform Act of 1995)所定義的前瞻性陳述,包括對 2026 年預期財務結果的說明。
The Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year ended December 31, 2025.
雅培提醒,這些前瞻性陳述受各項風險與不確定性影響,可能導致實際結果與前瞻性陳述所示存在重大差異。可能影響雅培營運的經濟、競爭、政府、技術及其他因素,已於我們截至 2025 年 12 月 31 日止年度之 Form 10-K 年報第 1A 項「風險因素」(Risk Factors)中討論。
Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at Abbott.com.
除法律要求外,雅培不承擔因後續事件或發展而公開發布任何前瞻性陳述修訂的義務。如同以往,今天的電話會議將使用非 GAAP 財務衡量指標,以協助投資人了解雅培持續性業務表現。這些非 GAAP 財務衡量指標已在我們今日發布的財報新聞稿與監管申報文件中與可比 GAAP 財務衡量指標進行調節,相關資料可於 Abbott.com 網站取得。
Note that Abbott has not provided the related GAAP financial measures on a forward-looking basis for the non-GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty and without unreasonable effort, the timing and impact of certain items, which could significantly impact Abbott's results in accordance with GAAP.
請注意,對於我們所提供指引的非 GAAP 財務衡量指標,雅培未以前瞻性基礎提供相關 GAAP 財務衡量指標,因公司無法在合理確定性且不需付出不合理努力的情況下,預測某些項目的發生時點與影響;而這些項目可能依 GAAP 對雅培結果造成重大影響。
Unless otherwise noted, our commentary on sales growth refers to comparable sales growth, which includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026.
除非另有說明,我們對銷售成長的評論係指可比銷售成長(comparable sales growth),其中包含雅培於 2026 年 3 月 23 日收購之癌症診斷公司 Exact Sciences 在前一年與本年度的銷售。
Our definition of comparable sales growth can be found on page 2 of our press release issued earlier today and a reconciliation table that contains data needed to calculate comparable sales growth can be found on page 13. With that, I will now turn the call over to Robert.
我們對可比銷售成長的定義載於今日稍早發布之新聞稿第 2 頁;包含計算可比銷售成長所需資料的調節表載於第 13 頁。接下來我將把電話會議交給 Robert。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Thanks, Mike. Good morning, everyone, and thank you for joining us. Our results in the first quarter were aligned with our expectations for the start of the year. That included delivering adjusted earnings per share of $1.15, consistent with our guidance despite absorbing the impact of earlier than planned financing costs related to our acquisition of Exact Sciences and a weaker-than-expected respiratory season.
謝謝你,Mike。各位早安,感謝大家加入我們。我們第一季的結果符合我們對年度開局的預期。其中包括在吸收較原先規劃更早發生、與收購 Exact Sciences 相關的融資成本影響,以及呼吸道季節弱於預期的情況下,仍交出調整後每股盈餘(adjusted EPS)1.15 美元,與我們的指引一致。
This quarter also marked an important strategic milestone for Abbott with the completion of our acquisition of Exact Sciences. This acquisition adds a new high-growth business to the Abbott portfolio. further strengthening our leadership position in diagnostics and expanding our presence into one of the fastest-growing areas of healthcare cancer diagnostics.
本季也為雅培完成收購 Exact Sciences 立下重要的策略里程碑。此項收購為雅培的產品組合新增一項高成長業務,進一步強化我們在診斷領域的領導地位,並將我們的布局擴展至醫療保健中成長最快的領域之一——癌症診斷。
As we communicated at the time of the acquisition announcement, we forecast the addition of Exact Sciences adds approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate.
正如我們在宣布收購時所溝通的,我們預估納入 Exact Sciences 將在 2026 年帶來約 30 億美元的增量銷售,並加速雅培的長期銷售成長率。
Before I summarize our first quarter results, I wanted to highlight a few pipeline achievements in our Medical Device business, and those include an earlier-than-planned approval and launch of two new PFA catheters, completion of patient enrollment in our catalyst, left atrial appendage device trial, initiation of development activities to bring an implantable extravascular ICD product to market and the announcement of positive results from our randomized controlled trial, which demonstrated that people with type 2 diabetes on basal insulin therapy benefited from using Libre, including seeing reductions in HbA1c and increased time spent in the healthy glucose range.
在我總結第一季結果之前,我想先強調我們醫療器材業務在研發管線上的幾項成果,包括兩款新 PFA 導管較原計畫更早獲准並上市、完成我們 Catalyst 左心耳封堵裝置試驗的病患收案、啟動開發活動以將可植入式血管外 ICD 產品推向市場,以及公布隨機對照試驗的正面結果;該試驗顯示,接受基礎胰島素治療的第二型糖尿病患者使用 Libre 可獲益,包括 HbA1c 降低以及處於健康血糖範圍的時間增加。
In addition to these achievements, our teams are preparing to initiate patient enrollment in several important clinical trials in the second half of this year. These trials represent a unique opportunity to position Abbott to bring a new wave of highly differentiated technologies to the market.
除上述成果外,我們的團隊也正準備在今年下半年啟動數項重要臨床試驗的病患收案。這些試驗代表一個獨特機會,可使雅培在市場上推出新一波高度差異化技術。
This pipeline of new technologies includes a balloon expandable TAVR valve, a leadless conduction system pacing device that utilizes our revolutionary other leadless pacemaker, a mitral replacement valve developed following our acquisition of Cephea Valve Technologies, a peripheral IVL device developed following our acquisition of CSI and a wearable continuous lactate monitoring sensor that will monitor for sepsis following discharge from a hospital.
這項新技術研發管線包括:球囊擴張式 TAVR 瓣膜、利用我們革命性其他無導線心律調節器的無導線傳導系統起搏裝置、在收購 Cephea Valve Technologies 後開發的二尖瓣置換瓣膜、在收購 CSI 後開發的周邊 IVL 裝置,以及一款可穿戴式連續乳酸監測感測器,可在病患出院後監測敗血症風險。
I'll now summarize our first quarter results before I turn the call over to Phil, and I'll start with Diagnostics, where sales increased 2% on a comparable basis. In Core Lab Diagnostics growth of 3% was driven by growth in the US, Europe and Latin America. Sales of Core Lab diagnostic tests which excludes capital equipment and digital health solutions, increased on both a year-over-year and sequential basis, and this is a trend that we expect to continue and drive higher growth in the second half of the year compared to the first half.
接下來在我把電話會議交給 Phil 之前,我先總結第一季結果,從診斷業務開始,可比基礎下銷售成長 2%。在核心實驗室診斷(Core Lab Diagnostics)方面,3% 的成長由美國、歐洲與拉丁美洲的成長所帶動。核心實驗室診斷檢測的銷售(不含資本設備與數位健康解決方案)無論年增或季增皆有所提升;我們預期此趨勢將延續,並推動下半年相較上半年呈現更高成長。
In our Rapid and Molecular Diagnostics business, sales declined 10%, reflecting lower demand for respiratory virus testing due to a much weaker respiratory season compared to last year. And in cancer diagnostics, sales grew 13% on a comparable basis, driven by mid-teens growth of Cologuard and high-teens growth in international markets.
在我們的快速與分子診斷(Rapid and Molecular Diagnostics)業務方面,銷售下滑 10%,反映相較去年呼吸道季節大幅轉弱,導致呼吸道病毒檢測需求降低。而在癌症診斷方面,可比基礎下銷售成長 13%,主要由 Cologuard 的約十多個百分點成長,以及國際市場約十多個百分點後段(high-teens)的成長所帶動。
Moving to Nutrition where sales finished slightly ahead of our expectations for the quarter. As discussed on our January earnings call, results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025 with an objective of reaccelerating volume growth.
接著看營養品(Nutrition),本季銷售略優於我們的預期。如同我們在 1 月財報電話會議所討論,本季結果反映相較前一年銷量較低的影響,以及 2025 年第四季所採取策略性定價措施的效果;該措施旨在重新加速銷量成長。
While we are still early in the transition back toward a more sustainable balance between price and volume-driven growth, I'm encouraged by the progress we're making. Early data indicates we are seeing the intended effect with volume growth beginning to follow our pricing actions. We continue to expect that these pricing actions, combined with the launch of several new products will result in growth improving over the course of the year.
雖然我們仍處於回到更可持續的「價格與銷量驅動成長」平衡的早期階段,但我對目前的進展感到鼓舞。初步數據顯示,我們正看到預期效果,銷量成長開始跟隨我們的定價行動。我們仍預期,這些定價行動加上數項新產品上市,將使成長在全年過程中逐步改善。
Turning to EPD, our pharmaceutical business, where sales increased 9% in the quarter. Growth was broad-based across the markets we serve, which included double-digit growth in several countries across Latin America and Asia Pacific regions.
再來看 EPD(我們的製藥業務),本季銷售成長 9%。成長動能遍及我們服務的各市場,其中包括拉丁美洲與亞太地區多個國家達到雙位數成長。
Demand in these markets continues to be supported by favorable long-term healthcare economic and demographic trends with a broad product offering across five therapeutic areas and an expanding biosimilars portfolio, which includes several market-leading oncology therapies, we are well positioned to serve the growing customer base in these markets.
這些市場的需求持續受到有利的長期醫療保健經濟與人口結構趨勢所支撐。憑藉涵蓋五大治療領域的廣泛產品組合,以及持續擴大的生物相似藥(biosimilars)產品線(其中包含多項市場領先的腫瘤治療),我們已具備良好定位,可服務這些市場日益成長的客戶群。
And I'll wrap up with Medical Devices, where sales grew 8.5%. Growth was led by strong performance in our cardiovascular device businesses. This included double-digit growth in Electrophysiology, Heart Failure and Rhythm Management. In Electrophysiology, growth of 13% included contributions from two pulse field ablation catheter launches in the quarter.
最後是醫療器材(Medical Devices),銷售成長 8.5%。成長主要由我們心血管器材業務的強勁表現所帶動,其中電生理(Electrophysiology)、心衰竭(Heart Failure)與節律管理(Rhythm Management)皆達到雙位數成長。在電生理方面,13% 的成長包含本季兩款脈衝場消融(pulse field ablation)導管上市的貢獻。
The launch of our Volt PFA catheter contributed to a growth of 14% in the US and the launch of our TactiFlex duo catheter helped drive mid-teens growth in Europe. As we broaden the launch of both catheters, we expect growth in our electrophysiology business to accelerate. In Rhythm Management, sales grew 13%, making the third consecutive quarter that we have delivered double-digit growth and continued our track record of significantly outperforming the market.
我們 Volt PFA 導管的上市帶動美國成長 14%,而 TactiFlex duo 導管的上市則有助推動歐洲約十多個百分點(mid-teens)的成長。隨著我們擴大兩款導管的上市範圍,我們預期電生理業務的成長將加速。在節律管理方面,銷售成長 13%,這是我們連續第三季達成雙位數成長,並延續我們顯著優於市場的表現紀錄。
In Heart Failure, growth of 12% was driven by our market-leading portfolio of heart assist devices, which offer treatment for chronic and temporary conditions. In Diabetes Care, continuous glucose monitoring sales were $2 billion and grew 7.5%. Growth in the quarter reflects an impact from a delay in the renewal process related to an international tender.
在心衰竭方面,12% 的成長由我們市場領先的心臟輔助裝置產品組合所帶動,該組合可提供慢性與暫時性病況的治療。在糖尿病照護(Diabetes Care)方面,連續血糖監測(CGM)銷售為 20 億美元,成長 7.5%。本季成長反映國際標案相關續約流程延遲所造成的影響。
We also saw the expected impact from a challenging comparison to last year. This comparison relates to shelf restocking dynamics that occurred in the first half of 2025, a topic that we discussed on our earnings call last year. As we look forward to the second quarter, we expect CGM to return to double-digit growth. So in summary, our results in the quarter were in line with our expectations to start the year.
我們也如預期看到與去年相比的艱難比較基期所帶來的影響。此比較與 2025 年上半年發生的通路補庫存動態有關,這也是我們去年財報電話會議中討論過的主題。展望第二季,我們預期 CGM 將回到雙位數成長。總結而言,本季結果符合我們對年度開局的預期。
We remain confident in our expectation for an acceleration in growth in the second half of the year, and we have clear visibility to the key drivers of that acceleration and are highly focused on executing on them. Those drivers include, first, executing our growth strategy in Nutrition, which is underway and on track with our expectations. Second, we see a clear path to accelerating growth in both Electrophysiology and Core Lab Diagnostics supported by best-in-class portfolios, new product launches and improving market conditions. Third, we will continue our proven track record of delivering strong, sustainable performance in EPD and across our Medical Devices portfolio. And finally, we are successfully integrating Exact Sciences, which adds a compelling high-growth business to the Abbott portfolio further strengthening our ability to deliver long-term sustainable growth. I'll now turn over the call to Phil.
我們仍然有信心,預期今年下半年成長將加速;而且我們對推動這一加速的關鍵驅動因素有清楚的能見度,並高度專注於落實執行。這些驅動因素包括:第一,執行我們在營養業務的成長策略,目前已在推進中,且進度符合我們的預期。第二,我們看到在電生理與核心實驗室診斷兩大業務上,加速成長有明確路徑,並由同級最佳的產品組合、新產品上市以及市場環境改善所支撐。第三,我們將持續在 EPD 以及整體醫療器材產品組合上,延續我們已被驗證的強勁且可持續的績效表現。最後,我們正成功整合 Exact Sciences,為 Abbott 產品組合增添一項具吸引力的高成長業務,進一步強化我們實現長期可持續成長的能力。接下來我把電話交給 Phil。
Phil Boudreau - Executive Vice President, Finance & Chief Financial Officer
Phil Boudreau - Executive Vice President, Finance & Chief Financial Officer
Thanks, Robert. As a result of the March 23rd, close of our acquisition of Exact Sciences, our first quarter financial results include the results of the Exact Sciences business from the close date through the end of the quarter. As Mike mentioned, our press release issued this morning provides sales growth in the quarter on a comparable basis, which includes the full quarter sales of Exact Sciences in both the prior and current year.
謝謝,Robert。由於我們於 3 月 23 日完成對 Exact Sciences 的收購交割,我們第一季財務結果包含自交割日起至季末期間的 Exact Sciences 業務表現。如 Mike 所提到,我們今天早上發布的新聞稿提供了以可比基礎計算的本季銷售成長,其中在前一年與本年度皆納入 Exact Sciences 的完整季度銷售額。
To align with our reporting of comparable sales growth, our full year 2026 sales growth outlook of 6.5% to 7.5% is now on a comparable basis as well. The sales growth outlook includes the full year sales of Exact Sciences in both the prior and current year.
為了與我們對可比銷售成長的揭露方式一致,我們對 2026 年全年 6.5% 至 7.5% 的銷售成長展望,現在也同樣改以可比基礎呈現。該銷售成長展望在前一年與本年度皆包含 Exact Sciences 的全年銷售額。
Compared to our previous full year adjusted earnings per share guidance range midpoint of $5.68, our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition, consistent with our assumption at the time of the announced transaction.
相較於我們先前全年調整後每股盈餘(adjusted EPS)指引區間中點的 5.68 美元,我們新的指引區間中點 5.48 美元反映了因收購 Exact Sciences 所帶來的 0.20 美元稀釋,與我們在宣布交易時的假設一致。
Turning to our first quarter results. Sales increased 3.7% on a comparable basis and adjusted earnings per share of $1.15 grew 6% compared to the prior year. Foreign exchange had a favorable year-over-year impact of 4% on first quarter sales. Earlier in the quarter, we saw the US dollar weakened, which resulted in a favorable impact on sales compared to exchange rates at the time of our earnings call in January. Regarding other aspects of the P&L, the adjusted gross margin profile was 56.3% of sales. Adjusted R&D was 6.7% of sales, and adjusted SG&A was 29.3% of sales.
接著看第一季結果。以可比基礎計算,銷售成長 3.7%;調整後每股盈餘為 1.15 美元,較去年成長 6%。外匯對第一季銷售的年對年影響為正向 4%。在本季較早時期,我們看到美元走弱,使得相較於我們 1 月財報電話會議時的匯率水準,對銷售帶來較有利的影響。至於損益表的其他項目,調整後毛利率為銷售額的 56.3%;調整後研發費用為銷售額的 6.7%;調整後銷售、一般及行政費用(SG&A)為銷售額的 29.3%。
Based on current rates, we expect exchange to have a favorable impact of approximately 1% on full year reported sales. For the second quarter, we expect exchange to have a relatively neutral impact on sales. And for the second quarter, we forecast adjusted earnings per share of $1.25 to $1.31. With that, we'll now open the call for questions.
以目前匯率水準來看,我們預期外匯對全年已報告銷售額將帶來約 1% 的正向影響。第二季方面,我們預期外匯對銷售的影響大致中性。同時,第二季我們預估調整後每股盈餘為 1.25 至 1.31 美元。接下來我們開放提問。
Q&A
問答
Operator
Operator
(Operator Instructions)
(接線員指示)
David Roman, Goldman Sachs.
David Roman,高盛。
David Roman - Analyst
David Roman - Analyst
Thank you, and good morning, everyone. Thanks for taking the question. Maybe I'll start with just the updated guidance, and I know you touched on some of this during the call. But maybe you could just go into some further detail on, firstly, maybe just your guidance philosophy and your just thought process in establishing the revised outlook.
謝謝,各位早安。謝謝讓我提問。我想先從更新後的指引開始,我知道你們在電話會議中已提到其中一些內容。不過也許你們可以再更詳細說明:第一,關於你們的指引理念,以及在建立修訂後展望時的思考流程。
And then secondly, just the extent to which the outlook is, in your mind, sort of fully derisks and captures upside potential, but also contemplates any downside unforeseen risks here?
第二,就你們的看法而言,這份展望在多大程度上已充分去風險化並涵蓋上行潛力,同時也納入任何下行的、不可預見的風險?
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Yeah, sure. I think the philosophy here, David, is I think maybe there's a portion there that is -- we've included Exact Sciences into the history and our philosophy there has always been to ensure that our investors have a clear transparent detailed kind of breakdown of our performance.
好的,當然。我認為這裡的理念是,David,我想其中有一部分是——我們已把 Exact Sciences 納入歷史數據;而我們一向的理念是,確保投資人能清楚、透明且具細節地了解我們的表現拆解。
We did that during COVID if you remember, we always split out the COVID sales, we got feedback that they really wanted to understand underlying part of the business and the COVID part of the business. When we did the acquisition of St. Jude, the acquisition closed in the first quarter and so we did the same approach there to fold in St. Jude into a kind of more comparable basis and we just think it provides the investors really the most relevant growth rate, a growth rate that is of the new Abbott portfolio on a very kind of clean apples-to-apples basis.
如果你還記得,我們在 COVID 期間也這麼做:我們總是把 COVID 的銷售額拆分出來;我們收到的回饋是,他們確實希望了解業務的基本面部分以及 COVID 相關部分。當我們收購 St. Jude 時,交易在第一季完成交割,因此我們也採取相同做法,把 St. Jude 納入以更可比的基礎呈現;我們認為這能為投資人提供最相關的成長率,也就是以非常乾淨、同類相較(apples-to-apples)的方式,呈現新的 Abbott 產品組合的成長率。
So I think that's the philosophy there. As it relates to the guidance, I think maybe the view there was just maybe a little bit of a -- I think a little bit of a conservative side here on some aspects that we felt in the first quarter. For example, if you look at the respiratory season, we forecast Q1 to be a relatively weak season compared to other seasons that we had seen in the past.
所以我認為理念是這樣。至於指引本身,我想我們的看法可能是在某些面向上稍微偏保守,因為第一季我們感受到一些情況。舉例來說,如果你看呼吸道季節,我們原先預估第一季會是相對偏弱的一季,與過去其他季節相比。
And then that was even weaker than what we had forecasted. And I think as we've looked at other comparable healthcare businesses that we look at, like, for example, like OTC meds, which is a very good kind of triangulation there. We're seeing also those types of businesses have kind of this year-over-year effect there.
而實際上又比我們預估的更弱。並且當我們觀察其他可比的醫療保健業務,例如 OTC 藥品(這是一個很好的交叉驗證指標),我們也看到這類業務同樣出現年對年的影響。
So one of the ways to think about it is like, okay, you have two parts in the year where you're going to have this effect. You have it at the beginning of the year and they have it at the end of the year. So one of the ways to think about it is, okay, we're going to make that lower respiratory season the back end of the year. And then we would have to assume that you would have an above-average respiratory season, at least from a testing perspective. But I'm only going to find that out just before Thanksgiving.
因此其中一種思考方式是:好,你一年中會有兩個時點出現這種影響——年初會有一次,年底也會有一次。所以另一種看法是:好,我們把這個較弱的呼吸道季節影響放到年底。那麼你就必須假設,至少從檢測需求的角度來看,第四季會出現一個高於平均的呼吸道季節。但我只能在感恩節前不久才會知道。
So I just thought it was prudent to say we're not going to be able to make up or I'll put it this way, I'm not going to forecast that we're going to make it up in Q4 this respiratory aspect. That doesn't mean we won't be ready.
所以我認為審慎起見,我們不會說我們能在第四季把這個呼吸道相關的缺口補回來——或者換句話說,我不會在預測中假設我們會在第四季把它補回來。這不代表我們不會做好準備。
Obviously, you know our portfolio, and we know we've got the manufacturing capabilities and the distribution to be able to do that. I just decided that I didn't think it was prudent to bake that into the forecast. The rest of the areas of the business, the sales growth outlook is very much in line with our January outlook and if I go back to the way I described our year over year progression, there's a couple of key kind of blocks that really drive our growth throughout the year.
顯然,你了解我們的產品組合;我們也知道我們具備製造能力與通路配送能力來支撐這件事。我只是判斷,把它直接納入預測並不審慎。至於業務的其他領域,銷售成長展望基本上與我們 1 月的展望非常一致;如果我回到我描述年對年進展的方式,全年成長主要由幾個關鍵區塊所驅動。
I'd say the first block here is just, as I said in my comments, sustaining the growth of our medtech business and our pharma business. Medtech business, low double digits; our pharma business, above 7%. These are businesses that have consistently and reliably delivered this type of performance and whether it's market conditions or new product launches in these businesses, we feel very good about our ability to be able to sustain that kind of performance.
我會說第一個區塊是,如我在評論中提到的,維持我們醫療科技(medtech)業務與製藥業務的成長。醫療科技業務為低雙位數成長;製藥業務為高於 7%。這些業務一向穩定且可靠地交出這類表現;不論是市場環境或新產品上市,我們對於維持這種表現的能力都很有信心。
The other bucket, I would say, the second bucket would probably be more, okay, trajectory changing businesses. And I would put diagnostics, especially our core lab business and Nutrition into those buckets. I think they're a little bit different, though, David. I would say on our Core Lab business, and we talked about this last year, the impact of China and the VBP and obviously, COVID, that was about a $1 billion headwind that we faced last year.
另一個類別,我會說第二個類別可能更偏向:好,屬於成長軌跡正在改變的業務。我會把診斷業務(尤其是我們的核心實驗室業務)以及營養業務歸在這一類。不過我認為它們有些不同,David。以核心實驗室業務來說,我們去年談過,中國的影響、VBP(帶量採購),以及顯然還有 COVID,去年合計約帶來 10 億美元的逆風。
Other parts of the business geography, other parts of the platform is doing very well, and we continue to see that. So what I've seen over the last 6 months really gives me confidence that we're actually very much either on track or slightly ahead of that recovery in our diagnostics and that growth trajectory change. And I think the teams there have done an incredible job in China and especially here in the US where, I think the team has done really good in terms of being able to capture market share.
而在其他地區、以及平台的其他部分,表現非常好,我們也持續看到這點。因此,過去 6 個月我所看到的情況,讓我有信心:我們的診斷業務復甦以及成長軌跡的轉變,實際上非常符合進度,甚至略微超前。我也認為團隊在中國做得非常出色,尤其是在美國,我認為團隊在搶占市占率方面做得很好。
The Nutrition transition, I think, is a little bit earlier on in that stage. But I still feel that what we're seeing right now, the decisions that we took, the timely decisions that we took in middle of Q4, I think we're starting to see some of that activity right now in terms of being able to drive volume growth.
至於營養業務的轉型,我認為仍處於較早期的階段。但我仍然覺得,我們目前看到的情況、以及我們在第四季中段所做的及時決策,我認為我們現在開始看到一些成效,特別是在推動銷量成長方面。
It's still early. I can't declare like, yes, it's done. But we're starting to see really good indications that the actions that we took and then combined with the new product launches that we're going to see that recovery.
現在仍然還早。我不能直接宣告說:是的,已經完成了。但我們開始看到非常好的跡象,顯示我們採取的行動,再加上即將推出的新產品,將帶動那個復甦。
And then the third bucket I would put on that list is just the integration of Exact Sciences, which adds a high-growth business to the portfolio. It's been performing very well. I'm sure we'll talk about that also. But I'd say those are the three kinds of big drivers of our sales forecast and those really haven't changed. So the real thing here was just I'm not going to try and call what type of flu season we're going to have starting before Thanksgiving.
然後我會把第三個「桶」放在那份清單上,就是 Exact Sciences 的整合,這為投資組合增加了一個高成長的業務。它的表現一直非常好。我相信我們也會談到這一點。但我會說,這三項就是我們銷售預測的三個主要驅動因素,而且這些其實都沒有改變。所以這裡真正的重點只是:我不會在感恩節之前就試著去預測我們會遇到什麼樣的流感季。
So if the flu season is as aggressive as we've seen in other years, then we have the manufacturing, we have the distribution, we have the sales force, all of that in place to be able to do that. So hopefully, that answers your question.
所以如果流感季像我們在其他年份看到的那樣猛烈,那麼我們具備製造能力、具備配送能力、也有銷售團隊,所有這些都已經就位,能夠支撐我們去應對。因此,希望這回答了你的問題。
Operator
Operator
Robbie Marcus, JPMorgan.
Robbie Marcus,摩根大通。
Robert Marcus - Analyst
Robert Marcus - Analyst
Great. Good morning, and thanks for taking the question. Robert, maybe to follow up on David's question. I appreciate that comparable growth is much more helpful metric, especially if we're looking out to the future and what the new Abbott will be doing on an underlying basis.
很好。早安,謝謝讓我提問。Robert,或許接續 David 的問題。我理解可比成長是一個更有幫助的衡量指標,特別是如果我們把視野放到未來、看新的 Abbott 在基本面上的表現。
But when I look at organic growth, which I think is what a lot of people pay attention to and the health of the Abbott business coming into the year before the acquisition, it looks to me like growth is moving from the 6.5% to 7.5% guide on the fourth quarter call. It's something more like 5.75% to 6.75% if we adjust out Exact Sciences and the lost royalty revenue. So it does look like there's a bit of deceleration in the prior organic Abbott business. How are you thinking about managing that? How much is one time versus sustainable and where do you see sort of the biggest pressure points and how you're addressing it? Appreciate it.
但當我看有機成長(我認為很多人會關注這個,以及收購前 Abbott 在進入年度時的業務健康度),在我看來,成長似乎是從第四季電話會議所給的 6.5% 到 7.5% 指引,變成如果把 Exact Sciences 以及流失的權利金收入調整掉之後,大概是 5.75% 到 6.75%。所以看起來,先前 Abbott 的有機業務確實有些放緩。你們如何思考並管理這件事?其中有多少是一次性因素、多少是可持續的?你們看到最大的壓力點在哪裡,又如何因應?謝謝。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Yeah, I'm not sure I followed those numbers though, Robbie. But I think what you're trying to get to is, hey, by putting Exact Sciences into a comparable basis are there parts of the non Exact business that are underperforming. I'm assuming that's what you're trying to hint around. I would say, as I said to David, I'll put it this way, if the business acquisition had closed after this call, let's call it sometime in Q2, I think we probably would have done, what you in the medtech space usually expect, is that you kind of keep it separate and then you kind of lap for the year. But then, what you'll then ask me to do is to always - every quarter reconcile between what the acquisition did to the organic growth rate.
是的,Robbie,不過我不確定我有完全跟上你那些數字。但我想你要問的是:把 Exact Sciences 納入可比基礎之後,非 Exact 的業務裡是否有些部分表現不如預期。我猜你是在暗示這個。我會說,就像我對 David 說的,我換個方式講:如果這筆收購是在這通電話之後才完成,假設是在第二季某個時間點完成,我想我們大概會採取醫療科技領域常見的做法,也就是先把它分開呈現,然後在一年之後再「同基期比較」。但接下來你們就會要求我每一季都去調節(reconcile)收購對有機成長率的影響。
So I just felt that because it was early in the Q1 before this call, that we could roll it in on a comparable basis and that would give our investors full visibility to the new Abbott with this addition of Exact Sciences. And so I don't think -- I know that might involve a little bit more work for some of you guys in terms of your modeling, all of that. But I think we try to make it very easy for you as part of our disclosures. Parts of the business that we're focusing on. I think I went through that in a fair amount of detail here.
所以我只是覺得,因為它是在第一季、而且在這通電話之前就已經完成,我們可以用可比基礎把它併進來,讓投資人能完整看見加入 Exact Sciences 之後的「新 Abbott」。因此我不認為——我知道這可能會讓你們在建模上需要多做一些工作等等。但我認為我們在揭露資訊時,已經盡量讓你們很容易掌握。我們聚焦的業務部分,我在這裡也講得相當詳細了。
I mean if you want to go to specific kind of parts of the portfolio we can, but I think I described that to David pretty clear here. But I'll repeat it, if necessary, the device portfolio, the pharma portfolio, we still feel very strong about those growth rates. We're not backing off of those. Obviously, there's opportunities to outperform in some of them. There are some more, kind of challenging areas in others, whether it's market, whether it's competition, but overall, that combination, we feel very good about sustaining that. And then these trajectory changing businesses, like we've discussed in Diagnostics and core nutrition.
如果你想談投資組合中更具體的部分,我們也可以談,但我想我剛才對 David 已經說得很清楚了。不過如有需要我可以再重申:器材(device)組合、製藥(pharma)組合,我們仍然對那些成長率非常有信心,並沒有要下修。當然,其中一些有機會超越預期;另一些則有比較具挑戰的領域,可能是市場因素、也可能是競爭因素。但整體而言,這樣的組合我們對其可持續性非常有信心。然後還有這些能改變成長軌跡的業務,如我們在診斷(Diagnostics)與核心營養(core nutrition)所討論的。
I think we know what the issues were. We know what we're working on, and we're really focused on executing that. But if I take a step back here, I mean, I think ultimately, the way our business is, we're a very diversified company. We lay out all of the different businesses. We break out even within sectors, we break them out and be able to show the performance in that.
我想我們知道問題是什麼,也知道我們正在做什麼,我們非常專注於把執行做好。但如果我退一步看,我們的業務本質上是一家非常多元化的公司。我們把所有不同的業務都攤開來看;甚至在各個事業部門之內,我們也會再拆分,並能夠展示其表現。
My view here is that, yes, it would be great to have every single business beating all the Street expectations. Unfortunately, sometimes you're not going to have that. I'm not going to say that never happens because it's happened before, but sometimes it doesn't happen.
我的看法是:是的,如果每一個業務都能超越華爾街的所有預期,那當然很好。不幸的是,有時候你不會做到每一個都如此。我不會說那永遠不會發生,因為以前也發生過,但有時候就是不會。
And I think the important thing there, Robbie, is that you have a collection of businesses that we feel are very attractive and that the combination that some of them are able to hit our commitments and deliver on our financial commitments. So I take a view of -- I look at each business individually, but we also look at it as a whole and I think as a whole to the company is well set up for this year.
而我認為重要的是,Robbie,你擁有一組我們認為非常有吸引力的業務組合,而這個組合中有些業務能夠達成我們的承諾、並交付我們的財務承諾。所以我的觀點是——我會逐一看每個業務,但也會把它當作整體來看;而我認為就公司整體而言,今年的布局是很到位的。
Robert Marcus - Analyst
Robert Marcus - Analyst
Thanks, Robert. Appreciate it.
謝謝你,Robert。很感謝。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Sure.
當然。
Operator
Operator
Larry Biegelsen, Wells Fargo.
Larry Biegelsen,富國銀行。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
Good morning. Thanks for taking the question. So Robert, I wanted to ask about CGM. We heard your comments about the CGM market or your business in Q1 and the expected acceleration in Q2, but the CGM prescription trends in the US look weak. Can you talk about what's happening in the CGM market? There's a concern that the current indications are saturated.
早安,謝謝讓我提問。Robert,我想問一下 CGM。我們聽到你對第一季 CGM 市場或你們業務的評論,以及第二季預期會加速,但美國的 CGM 處方趨勢看起來偏弱。你能談談 CGM 市場正在發生什麼嗎?市場上有人擔心目前的適應症已經飽和。
How are you thinking about Libre growth the rest of the year and longer term? And just lastly, remind us of the timing for type 2 non-insulin and the dual ketone sensor and the lactate sensor you mentioned? Thank you.
你如何看待 Libre 在今年剩餘時間以及更長期的成長?最後,也請你提醒我們:你提到的第二型糖尿病非胰島素族群,以及雙酮體感測器與乳酸感測器,時間點分別是什麼?謝謝。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Sure. Listen, I think it's always important to look at weekly prescription data in one country. It's an important country. And the weekly prescription data is obviously great early indicators for the market, even though that auditing channel that you guys rely on to look at weekly prescription data doesn't capture the entire market. It's very different from pharma, where you've got a lot of other segments of the market that are performing.
好的。聽著,我認為看單一國家的每週處方資料一直都很重要。那是一個重要的國家。而每週處方資料顯然是市場很好的早期指標,儘管你們用來查看每週處方資料的那個稽核通路,並沒有涵蓋整個市場。這跟製藥很不一樣,製藥還有很多其他市場區隔在運作。
So I think using TRx data to ultimately look at how the market is evolving and only using that is, I would say -- I'd caution -- I think it's a little bit myopic. So let me take a kind of a bigger view here, okay, Larry in terms of how I think about the market, what's going on in the market and the opportunities we have there.
所以我認為,最終用 TRx(總處方量)資料來看市場如何演變、而且只用這個來看,我會說——我會提醒——這有點短視。讓我從更宏觀的角度來看,好嗎,Larry,談談我如何看這個市場、市場正在發生什麼,以及我們在其中的機會。
I'm very bullish on this market. If I look at the big picture here, I'm very bullish on the CGM market. As you know, Larry, I've always been, and I continue to be. If I look at our assessment of the amount of people that should be on a CGM on a global basis, we estimate between 70 million to 80 million people on CGMs -- should be. And obviously, there are different types of patients in that number, but overall, 70 to 80 million people.
我對這個市場非常看多。如果我看大局,我對 CGM 市場非常看多。你知道的,Larry,我一直都是,而且我仍然是。如果我看我們對全球應該使用 CGM 的人數評估,我們估計應該有 7,000 萬到 8,000 萬人使用 CGM——應該是。當然,這個數字包含不同類型的病患,但整體而言是 7,000 萬到 8,000 萬人。
I think the market today is around 10 million to 12 million, so 10 million to 12 million people and again, you might think 70 million, 80 million is a lot, but there's about 0.5 billion people with diabetes. So I felt that I've kind of narrowed it down quite a bit already. And even in that narrowed down world, we're still very under-penetrated. And I think if you look back to -- I'll speak for our growth trajectory because we've looked at this, and we continue to look at it. I go back like 15 years, I look at quarterly revenue over 15 years. So let's call it, whatever, 60 data points there. It's never always up to the right on a perfect 45-degree, okay?
我認為目前市場大約是 1,000 萬到 1,200 萬,也就是 1,000 萬到 1,200 萬人在使用;同樣地,你可能會覺得 7,000 萬、8,000 萬很多,但糖尿病患者大約有 5 億人。所以我覺得我其實已經把範圍縮小很多了。而即便在這個縮小後的世界裡,我們的滲透率仍然非常低。我想如果回頭看——我就以我們的成長軌跡來說,因為我們一直在看、也持續在看。我回溯大概 15 年,去看 15 年的季度營收。也就是說,大概有 60 個資料點。它不可能永遠都以完美的 45 度角一路向右上,好嗎?
I know we love businesses that are like that, but it never is. There are periods, if you look -at least for us, there are periods where there's a little bit of modest growth and modest growth, I'd call like whatever is 8% to 10%. And then it's followed by very long periods of strong, strong acceleration, teens and 20% kind of growth. And if you look at those acceleration periods, they're typically driven by different types of catalysts, either a reimbursement catalyst, a geographic expansion catalyst, a new product launch catalyst. And as I look at this market and I look at our position, I feel a lot of catalysts still ahead of us in this market.
我知道我們都喜歡那種一路向上的企業,但現實從來不是那樣。會有一些期間——至少對我們而言——會出現一段溫和成長、再一段溫和成長;我所謂溫和成長,大概就是 8% 到 10% 之類。然後接著會有很長一段非常強勁的加速期,出現十幾%、二十幾%的成長。而如果你看那些加速期,通常是由不同類型的催化劑所驅動:可能是給付(reimbursement)催化劑、地理擴張催化劑、新產品上市催化劑。當我看這個市場、看我們的定位時,我覺得在這個市場上,未來仍有很多催化劑在等著我們。
If I think about reimbursement as a strong catalyst, you just mentioned one. [CSM] type 2 non-insulin coverage. I expect proposed language of that coming soon. I can't tell you the exact month, Larry. And I'm not going to try and forecast what it is, when it is, but I know it's going to happen. And I know that it's going to add close to 10 million people that don't have coverage now that now will be able to have coverage.
如果我把報銷視為一個強力的催化劑,你剛才提到了一個。[CSM] 第 2 型非胰島素用藥的給付。我預期相關的擬議文字很快就會出來。我無法告訴你確切的月份,Larry。我也不會試圖去預測它是什麼、何時會發生,但我知道它一定會發生。而且我知道,這將為目前沒有給付的近 1,000 萬人新增給付,使他們現在能夠獲得給付。
And that's obviously going to accelerate commercial coverage, too. So I think that's one that we talked about. I have not included in my guidance. But it is a sweet spot for us in terms of our -- the channel -- our channel strength, our promotional strength reimbursement coverage there.
而這顯然也會加速商業保險的給付。因此我認為這是我們談到的一項。我沒有把它納入我的指引之中。但就我們而言,這正是甜蜜點,因為在那裡我們的——通路——通路優勢、推廣優勢以及報銷給付都很強。
So I think that's a count that's on the horizon here for us. Internationally, I know we like to focus a lot on the US but internationally, out of the top 10 markets in the world, only four have actually gone full-blown basal coverage.
所以我認為這是我們眼前即將到來的一個因素。國際方面,我知道我們很常把焦點放在美國,但在全球前 10 大市場中,實際上只有 4 個已經全面推行基礎胰島素(basal)給付。
So there are another six very large markets that are still in the process of not evaluating, but going through the budget process, the criteria process, et cetera. And what we've tried to do is obviously build evidence to be able to support that movement, not only from a physician side, but also from a patient advocacy.
因此還有另外 6 個非常大的市場,仍在進行中——不是在評估,而是在走預算流程、標準流程等等。我們所做的,顯然是建立證據來支持這個推進,不僅從醫師端,也從病患倡議端。
We showed an RCT, I talked about in opening comments at ATTD conference later this year, which showed, again, in a randomized controlled trial, not just using real-world evidence, but randomized controlled trial that patients on basal do better with Libre. So I look at those -- and there is so much opportunity still internationally and even in the US so I don't think that the patient TAM is tapped or anything like that.
我們展示了一項 RCT,我在今年稍晚的 ATTD 會議開場評論中提到過;該研究再次顯示,在隨機對照試驗中——不只是使用真實世界證據,而是隨機對照試驗——使用基礎胰島素的病患搭配 Libre 表現更好。所以我看待這些——國際上、甚至在美國仍有非常多機會,因此我不認為病患 TAM 已經被挖掘殆盡或類似情況。
You're just going to have these little moments where growth modulates a little bit and then the next catalysts come in and they continue to drop -- you have to look at the bigger picture, which is you've got 70 million to 80 million people that can be on this product. And even if you look at a yearly revenue number that's lower than what we're seeing today because you've got different types of patient groups in that number, you're looking at $30 billion, $35 billion TAM here that's available to us.
你只會看到一些小時刻,成長稍微調節一下,接著下一個催化劑出現,成長又會繼續——你必須看更大的圖景:有 7,000 萬到 8,000 萬人可以使用這個產品。即使你用一個年度營收數字來看,因為其中包含不同類型的病患族群,可能會低於我們今天看到的水準,你仍然是在看一個 300 億到 350 億美元的 TAM,這是我們可取得的市場。
And we're focused on that, Larry. We're focused on building a competitive advantage to be able to be a leader in that space, whether it's product technology advantage, cost advantage, scale advantage. And we do very well there and then if you think about kind of innovation as another catalyst, we have a couple that are on our way also for us, too.
而我們正專注於此,Larry。我們專注於建立競爭優勢,以便在那個領域成為領導者,不論是產品技術優勢、成本優勢、規模優勢。我們在那裡做得很好。再者,如果你把創新視為另一個催化劑,我們也有幾項正在路上。
We've got still committed to an expected approval of our dual analyte system in the second half of this year. That's going to open up about 1 million patients that we previously had very little access to on the pump side. You're going to have about 5 million SGLT2 users that aren't using the product, which will now have the benefit of having consumers ketone monitoring. We're working on a Libre 5. I'm not going to get ahead of myself here. But our view here is always, okay, how do we continue to sustain our competitive advantage and you do that through cost advantage and you do that through product innovation. So I still feel very good about this market.
我們仍然承諾,我們的雙分析物(dual analyte)系統預期會在今年下半年獲得核准。這將為我們打開約 100 萬名病患——在幫浦端我們過去幾乎很難觸及的族群。你還會有約 500 萬名 SGLT2 使用者目前沒有使用該產品,而他們將能受益於消費者端的酮體監測。我們也在開發 Libre 5。我不想在這裡超前透露太多。但我們的觀點一向是:好,如何持續維持我們的競爭優勢?你透過成本優勢與產品創新來做到這點。所以我對這個市場仍然感覺非常好。
And I'm looking at it from a much bigger picture than just weekly TRxs, which don't get me wrong. We look at it also, and we can see the trends, too, and there are obviously areas that we can do better, and we're working on that, too. But bigger picture here is that we're very well positioned for what I believe is a very, very large kind of market.
而我看待它的角度,是比每週 TRx(處方量)更宏觀的圖景——別誤會,我們也會看 TRx,也能看到趨勢;而且顯然有些地方我們可以做得更好,我們也正在努力。但更大的圖景是:我相信這是一個非常、非常龐大的市場,而我們的定位非常好。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
All right. Thanks so much.
好的。非常感謝。
Operator
Operator
Vijay Kumar, Evercore ISI.
Vijay Kumar,Evercore ISI。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Hi, Robert. Good morning and thank you for taking my question. I guess maybe I'll stick to Exact. Given that the deal is closed. This is an asset which has done phenomenally well over the years, doing mid-teens kind of growth. Just talk about your plans for sustaining strong growth of Cologuard. Is there an international angle here for Cologuard?
嗨,Robert。早安,謝謝你回答我的問題。我想我可能會聚焦在 Exact。鑑於交易已經完成,這是一項多年來表現非常出色的資產,呈現約十幾%中段的成長。請談談你們維持 Cologuard 強勁成長的計畫。Cologuard 在國際市場是否也有切入角度?
And sort of related to that , when I look at guidance. Comparable growth is now 6.5% to 7.5%, and we know Exact has grown faster. Is there some conservatism that's being perhaps being baked in the guidance? Could there be upside given Exact is growing faster? Thank you.
以及與此相關的,當我看你們的指引時,可比成長現在是 6.5% 到 7.5%,而我們知道 Exact 的成長更快。指引中是否可能納入了一些保守性?鑑於 Exact 成長更快,是否可能有上行空間?謝謝。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Sure. Listen, I think the integration is going very well. So I think it starts with that, right? We've named Jay Corbel, our new leader in that business. He previously led the screening business of the Cologuard business, and he's reporting directly to me.
當然。聽著,我認為整合進行得非常順利。我想一切就從這裡開始,對吧?我們任命了 Jay Corbel 作為該業務的新領導人。他先前領導 Cologuard 業務的篩檢部門,並且直接向我匯報。
It's reported in our diagnostics kind of queue, but operating stand-alone and a report straight to me. I think right now, we're very excited, and I know that the team is also very excited have had opportunities to field travel with the reps, I've got opportunities to talk to physicians. And I'd say I'm very bullish about the ability to really accelerate this business.
它在我們的診斷事業群中呈報,但以獨立方式營運並直接向我匯報。我認為目前我們非常興奮,我也知道團隊同樣非常興奮。我有機會跟著業務代表外出拜訪,也有機會與醫師交流。我會說,我對真正加速這項業務的能力非常看多。
Sustaining Cologuard growth. I'll answer that, but let me just say, when we looked at this strategically, Vijay, we really wanted to think about this not as a one product kind of deal, but more as an opportunity to enter a space that is extremely exciting and very high growth. So not just screening with Cologuard, but therapy selection and MRD testing. These are obviously areas that I know you know very well and they have great opportunities here.
維持 Cologuard 的成長——我會回答這點,但我先說,Vijay,當我們從策略角度看這件事時,我們真的不想把它視為一筆單一產品的交易,而更像是一個進入一個極其令人興奮且高成長領域的機會。因此不只是用 Cologuard 做篩檢,還包括治療選擇(therapy selection)與 MRD 檢測。這些顯然是我知道你非常熟悉的領域,而且在這裡有很大的機會。
So our goal in doing this is to actually be across the entire cancer diagnostics ban, and we believe that exact was definitely kind of a beachhead building block for us to do that and within that, obviously, Cologuard is the key growth driver there. And I would say, I think it's a very sustainable growth here for us for a couple of reasons. One, the demand is still going to is high and it's continued to increase, right? So right now, if you look at it's very under-penetrated right now.
因此我們做這件事的目標,是要涵蓋整個癌症診斷版圖,而我們相信 Exact 確實是我們達成這點的一個灘頭堡式的基礎建設;在其中,Cologuard 顯然是關鍵的成長驅動因素。我會說,我認為對我們而言這是非常可持續的成長,原因有幾個。第一,需求仍然很高,而且還在持續增加,對吧?所以如果你現在看,它的滲透率仍然非常低。
You've got 50 million Americans that are not up to date with our CRC screening. So there's an opportunity here in the US but internationally also, this is very under -- like very under-penetrated, Vijay. And one of the things that we bring is established regulatory KOL, health care system distribution relationships across a lot of markets.
有 5,000 萬美國人沒有按時完成我們的 CRC(大腸直腸癌)篩檢。因此在美國有機會;但在國際上也一樣,這仍然非常——非常低滲透,Vijay。而我們能帶來的一點,是在許多市場已建立的法規、KOL(關鍵意見領袖)以及醫療體系的通路分銷關係。
So we've already set aside a group that's really going to focus on how do we develop the screening and the cancer testing market in these international markets. And then if you look at screening guidelines, I mean, the age in '20 -- I think it was [2021] lowered from 50 to 45. That added a lot of new patients.
所以我們已經成立了一個團隊,將真正專注於:我們要如何在這些國際市場發展篩檢與癌症檢測市場。再者,如果你看篩檢指引,我是說,年齡在 '20——我想是 [2021]——從 50 歲下調到 45 歲。那新增了很多新病患。
What I'm seeing, and I think it's more than anecdotal. I've seen studies now that we're seeing people like at 30 and 35 be diagnosed with like stage 3 and so that's not good, obviously. So could I eventually see that being lowered from 45 down to 40. I think I can see that happening because there is a medical need for that, and that would add another 20 million people just in the US. So I think the demand is there.
我所看到的,而且我認為不只是軼事。我現在已經看到研究顯示,我們看到有人在 30、35 歲就被診斷為第 3 期之類的情況,這顯然不好。所以我是否最終會看到門檻從 45 歲再降到 40 歲?我認為我可以看到這件事發生,因為確實有醫療需求,而這僅在美國就會再增加 2,000 萬人。所以我認為需求是存在的。
The piece of the Cologuard, which is an incredible value proposition is that with this increasing demand for screening, there's only a certain -- (inaudible) colonoscopy capacity, at least in this country. It really hasn't changed. It's been $6 million per year and pretty consistently.
Cologuard 的一個部分——它是一個令人難以置信的價值主張——在於隨著篩檢需求增加,結腸鏡檢查的量能只有一定程度——(聽不清)——至少在這個國家是如此。它其實沒有改變,一直大約是每年 600 萬例,而且相當一致。
And if you factor in that there -- if you look at gastroenterologists and look at the enrollment rates in medical schools are coming down, so you can see a world where going to have increased demand for screening and less supply to be able to do that from a colonoscope perspective and Cologuard does really well here, not only is it convenient at-home, but its sensitivity at 95% is equivalent to colonoscopy.
而如果你把這點納入考量——如果你看腸胃科醫師的人數,以及醫學院的招收率正在下降——你就能想像一個世界:篩檢需求增加,但從結腸鏡角度來看,能提供的供給更少;而 Cologuard 在這裡表現非常好,不僅因為它方便、可在家完成,而且其 95% 的敏感度等同於結腸鏡。
So I think the combination of the increased demand followed by this bottleneck. If you look right now, I think in the US I was talking to the team average wait time for colonoscopies is between three to nine months, depending on the state. So it's already -- there's already a backlog. So I think the demand and the value proposition of Cologuard is very strong. And if I add a third part there, I think what the team at Exact Sciences has built is pretty unique.
所以我認為,需求增加再加上這個瓶頸的組合——如果你現在看,我想在美國我和團隊聊到,結腸鏡的平均等待時間介於 3 到 9 個月,取決於州別。所以已經——已經有積壓。因此我認為 Cologuard 的需求與價值主張非常強。如果我再加上第三點,我認為 Exact Sciences 團隊所建立的東西相當獨特。
So you've got a 1,000-person sales force calling on primary care reps, and it takes time to build that It's not an easy thing. And you've got 200,000 health care professionals prescribing every quarter, Cologuard. And they have this incredible system where everything is integrated. It's integrated into the health care records, it's integrated into your phone. I mean it's a very seamless experience.
所以你擁有一支1,000人的銷售團隊在拜訪基層醫療代表,而建立起這一切需要時間,這並不容易。而且每一季有20萬名醫療專業人員在開立Cologuard處方。他們有一套令人驚豔的系統,把所有事情都整合在一起:整合進醫療照護紀錄、整合進你的手機。我的意思是,這是一個非常無縫的體驗。
And I think that's pretty unique. I think the other part that is unique to us is that rescreens are becoming a very strong growth contributor. 25% of our tests today are rescreens and you're eligible for a rescreen every three years. When you've got all the data, you can obviously interact with your customers to remind them. And what I saw on the data was that you've got a very high rescreen rate, and it gets even higher as the rescreens kind of progress. So I think right now, we're seeing about 500,000 patients per year just for rescreens.
我認為這相當獨特。另一個對我們而言很獨特的部分是,複篩正成為非常強勁的成長貢獻來源。目前我們25%的檢測是複篩,而你每三年就符合一次複篩資格。當你掌握所有數據時,顯然可以與客戶互動並提醒他們。我從數據看到的是,你們的複篩率非常高,而且隨著複篩推進,複篩率還會更高。所以我認為目前我們每年僅複篩就約有50萬名病患。
So I think that -- that's something that's very unique to this business for us because they've been doing it for 10 years. So you've got this rescreen business that keeps on going. And then the third thing, which I think is also very unique to us and what's been built is these care gap programs, which I know you know very well also, CRC screening is one of the quality metrics that CMS uses for star ratings. And payers and providers, they get 3 times this quality score for Cologuard versus a FIT test.
所以我認為——這對我們來說是這項業務非常獨特的一點,因為他們已經做了10年。因此你有這個會持續進行的複篩業務。第三點,我認為同樣非常獨特、也是已建立起來的,是這些照護缺口(care gap)計畫;我知道你也非常熟悉。CRC篩檢是CMS用於星級評等的品質指標之一。而對於Cologuard,相較於FIT檢測,保險支付方與醫療提供者可獲得3倍的品質分數。
So we're seeing a lot of interest from health care systems and providers to stay ahead and ensure that they're scoring their quality metric points. So I think those three things are pretty unique. And I add that with a combination of the demand, the opportunity to international. So I feel very good about our ability to kind of sustain this growth. Now internationally, is it going to be Cologuard.
因此我們看到許多醫療體系與醫療提供者很有興趣,希望保持領先並確保他們能拿到品質指標的分數。我認為這三點相當獨特。再加上需求、以及國際化的機會。所以我對我們維持這種成長的能力感到非常有信心。至於國際市場,會是Cologuard嗎?
It could be in some markets, it could be other tests for other markets, but there's clearly your need here. I travel to Asia, I travel to Europe in this first quarter, and I spoke to health ministers and top 3 things that we walked away from was they want to get cancer screening up and going in their countries. They see it as a problem, and they see Abbott as one of those solutions.
在某些市場可能會是,在其他市場可能會是其他檢測,但這裡顯然存在需求。我在第一季前往亞洲、也前往歐洲,並與衛生部長交流;我們帶回來的前三大重點是:他們希望在其國家推動並提升癌症篩檢。他們把這視為一個問題,也把Abbott視為解決方案之一。
So I feel very good about this business and the integration is going very well. I couldn't have asked for a better integration. Culturally, I think both companies are very compatible, very focused on the patient and on innovation and driving growth. So we feel good about it.
所以我對這項業務感到非常樂觀,而整合進展也非常順利。我不可能要求更好的整合。從文化面來看,我認為兩家公司非常相容,都非常以病患為中心、重視創新並推動成長。所以我們對此感到很安心。
Operator
Operator
Matthew Taylor, Jefferies.
Matthew Taylor,Jefferies。
Matthew Taylor - Equity Analyst
Matthew Taylor - Equity Analyst
Good morning. Thanks for taking the question. I was hoping that you could talk a little bit about the trends in Structural Heart. And maybe within that, just to address what's going on in left atrial appendage closure. Not only do you have programs including the NextGen 360, which I think people are excited about, but I was hoping if you could comment on what you think the impact could be from the Champion study from your competitor, and you have a similar study catalyst that will read out here in a year or two, but would love kind of an overview of Structural Heart and LAAC.
早安。謝謝讓我提問。我希望你能談談結構性心臟(Structural Heart)的趨勢。也許在其中,談一下左心耳封堵(left atrial appendage closure)的情況。不僅你們有包含NextGen 360在內的計畫,我想大家都很期待;我也希望你能評論一下,你認為競爭對手的Champion研究可能帶來什麼影響。另外你們也有類似的研究催化劑,將在一到兩年內讀出結果,但我很想聽聽你對Structural Heart與LAAC的整體概覽。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Yeah, so I think that's an interesting question because I think historically, what we've done is we've had left atrial appendage closure device within our Structural Heart business and what we decided to do is to move it outside of our Structural Heart business and put it into our Electrophysiology business. And we did that in end of last year and beginning -- starting January 1, where we moved the sales force, clinical teams and eventually move manufacturing, et cetera, over.
是的,我認為這是個有趣的問題,因為歷史上我們一直把左心耳封堵裝置放在結構性心臟業務之內;而我們決定把它移出結構性心臟業務,放到我們的電生理(Electrophysiology)業務中。我們在去年年底以及今年年初——從1月1日開始——完成了這項調整,把銷售團隊、臨床團隊,並最終把製造等也一併移轉過去。
And we did that just because we felt that this would be beneficial for our Electrophysiology business, but quite frankly, it would be more beneficial for our Structural Heart business. So I'll focus on the Structural Heart business and the trends there. Listen, I think we've been doing pretty well with this business.
我們這麼做是因為我們覺得這對電生理業務有利,但坦白說,對結構性心臟業務更有利。所以我會聚焦在結構性心臟業務及其趨勢。聽著,我認為我們在這項業務上表現得相當不錯。
So when you look at the -- I think in our Q, we've got a reconciliation of the impact of moving those sales out of Structural Heart into EP. So that's a big contributor to the disconnection between The Street model and what we delivered.
所以當你看——我想在我們的Q(季度資料)裡,我們有一個調節表,說明把那些銷售從結構性心臟移到EP所帶來的影響。這是造成華爾街模型與我們實際交付結果之間落差的一個重要因素。
But on top of that, we have seen some competitive intensity increase here in the mitral space as one of our main competitors here has kind of expanded their portfolio. So yes, I think my team can do a better job there. They know that also. We need to improve our execution in the U.S.
但除此之外,我們也看到在二尖瓣領域的競爭強度有所提升,因為我們在這裡的一個主要競爭對手擴充了他們的產品組合。所以是的,我認為我的團隊可以在這方面做得更好,他們也知道。我們需要改善在美國的執行力。
We've done some changes to leadership. And I'm expecting our U.S. commercial team here to respond to the challenge. Internationally, growth continues to be very, very strong across the entire portfolio and we're delivering double-digit growth in mitral and TriClip, in our structural interventions business. So I think that's going very well.
我們已對領導團隊做了一些調整。我也期待我們在美國的商業團隊能回應這項挑戰。在國際市場方面,整個產品組合的成長仍然非常、非常強勁;在我們的結構性介入(structural interventions)業務中,二尖瓣與TriClip都實現了雙位數成長。所以我認為進展非常順利。
And while there's going to be some geographic differences there, Matt, and I think that geographic difference might persist for a little bit. I continue to expect our Structural Heart growth here to be high single digit for the full year. So I feel good about the Structural Heart portfolio.
當然在地理區域上會有一些差異,Matt,我認為這種地理差異可能還會持續一段時間。但我仍預期我們結構性心臟業務全年成長將維持在高個位數。因此我對結構性心臟產品組合感到很有信心。
There are areas that we got to do better in. I kind of highlighted the product and the geography. So -- and I'm expecting the team to really respond here. I think the business is doing very well and then as I said in my opening comments, we've got a couple of trial readouts, as you mentioned, we completed enrollment in our catalyst.
有些領域我們必須做得更好。我剛才也點出了產品與地理區域這兩點。所以——我期待團隊能在這裡真正做出回應。我認為業務表現非常好;另外如同我在開場所說,我們有幾項試驗結果即將讀出。正如你提到的,我們已完成我們催化劑研究的收案。
I don't have a big reaction to my competitor's trial. I'm going to let them as I'm assuming they probably have done -- talked about it. So I'm going to wait until ours comes out, and then I'll comment on ours. But I think it's a high-growth, attractive business.
我對競爭對手的試驗沒有太大的反應。我會讓他們去——我想他們可能已經談過了。所以我會等到我們的結果出來,再評論我們自己的。但我認為這是一個高成長、具吸引力的業務。
I think you mentioned our next-generation product. I think it is a very, very exciting product for us. And that's why we thought that moving it over to our EP business would actually provide a better acceleration for that product per se and then actually allow our Structural Heart team to be more focused on kind of valvular products and selling and keep them more focused.
我想你提到了我們的下一代產品。我認為那對我們來說是一個非常、非常令人振奮的產品。也正因如此,我們認為把它移到EP業務,實際上能讓該產品獲得更好的加速;同時也讓結構性心臟團隊能更專注在瓣膜類產品的推廣與銷售,保持更聚焦。
Matthew Taylor - Equity Analyst
Matthew Taylor - Equity Analyst
Thank you very much.
非常感謝。
Operator
Operator
Travis Steed, BofA Securities.
Travis Steed,BofA Securities。
Travis Steed - Analyst
Travis Steed - Analyst
Hey, everybody. I wanted to ask on the Nutrition business. And I heard you mention that volume is starting to recover. But any other color you can give on giving confidence in that business returning to growth in the back half and volume picking up? And then -- and how you're thinking about ongoing portfolio management and value creation and how nutrition fits in that strategic thinking?
嗨,各位。我想問營養品(Nutrition)業務。我聽到你提到銷量開始回升。但你還能提供哪些補充資訊,來讓大家對下半年該業務回到成長、以及銷量回升更有信心?另外——你如何看待持續的產品組合管理與價值創造,以及營養品在這個策略思考中扮演的角色?
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Yeah, sure. Like I said in my comments and in a couple of the early questions, I think we're starting to see that impact. We did a pretty comprehensive price assessment, not just at a product level, but a geographic level. We evaluated our gaps versus our competition.
好的,當然。如同我在評論以及前面幾個問題中所說,我認為我們開始看到那個影響。我們做了一個相當全面的定價評估,不僅在產品層級,也在地理區域層級。我們評估了相較於競爭對手的差距。
So we didn't reduce prices just basically uniformly across the portfolio, Travis. We kept it very focused on the products that we believe and based on our experience would demonstrate this positive volume response to a reduced price.
所以我們並不是在整個產品組合上做一致性的降價,Travis。我們把重點放在那些我們相信、且根據經驗判斷,在降價後會呈現正向銷量反應的產品上。
So when the price is passed on to the consumer, we're seeing this kind of immediate effect. But it takes time for some of that price to get passed on to the consumer, right? Because you've got inventory in the channel, et cetera.
因此當降價被傳導到消費者端時,我們看到這種立即的效果。但其中一部分價格傳導到消費者端需要時間,對吧?因為通路裡還有庫存等等。
So it doesn't -- so that price reset to the consumer doesn't happen overnight, which is why because we know that we wanted to get ahead of it as quickly as possible, which is why we did it in Q4 of last year. But when we lower -- when you see the lower prices get passed through the consumer, you're seeing the intended effect.
所以——面向消費者的價格重設不會一夕之間發生。也正因為我們知道要盡快提前布局,所以我們在去年第四季就做了。但當我們降低——當你看到較低的價格被傳導到消費者端時,你就會看到預期的效果。
So if you look, for example, that our US adult nutrition business, specifically on Ensure . That was a product that we knew had some elasticity and its price just based on our experience, we've seen volume grow across all the retailers that have actually passed that on here in the US pass that on to the consumer. So you're seeing that increase in volume, and we kind of use the 2025 as kind of the baseline. Obviously not Q4, but at least the first half of the year is the baseline.
例如,如果你看我們美國成人營養品業務,特別是Ensure。那是一個我們知道具有一定價格彈性的產品;根據我們的經驗,只要其價格調整到位,我們就看到在美國所有確實把降價傳導給消費者的零售商那裡,銷量都有成長。所以你會看到銷量上升,而我們大致把2025年作為基準。當然不是第四季,但至少上半年作為基準。
So we're tracking this on a monthly basis. I know my team looked at this on a weekly basis with the data that's available. So I feel good about where we are right now. I mean I'm not going to say right now that it's all done and let's just let time pass and then it will all come through. There's work we've got to do. There are product launches that also allow us to gain distribution. There's work that we need to do in terms of expanding distribution into the distribution channel.
所以我們是以每月為基礎追蹤這件事。我知道我的團隊也會用現有可得的數據按週檢視。因此我對我們目前的狀況感到有信心。我的意思是,我不會在此刻就說一切都完成了,然後就讓時間過去、事情自然就會好轉。我們還有工作要做。我們也有產品上市,這些也能讓我們取得更多通路覆蓋。我們也需要在把通路覆蓋擴展到分銷渠道方面持續努力。
So there's a lot of work going on right now, but the team is incredibly focused. And I think this is a team that's been pretty resilient, Travis, and does pretty well -- at least has shown to do pretty well when it counted some of these challenges, they are able to bounce back pretty quickly. So right now, I'd say on track, encouraging early signs, but still work to do. As it relates to the portfolio. Listen, I like the diversity of our business model and the diversity is not just across business segments, it's across products. It's the diversity in our geography, it's diversity in our customer base and different payer types and different innovation cycles. We don't want to be so heavily weighted on 1 or 2 products that the company has kind of driven there. And I think that diversity really provides us a pretty unique perspective on the global health care system. That being said, Travis, we're constantly looking at our portfolio, we're constantly looking at is the market still attractive? How is our competitive position that we can determine. Do we expand, do we maintain? Do you potentially reduce? And we do this on an ongoing basis with management, and we do it with our Board at least once a year, sometimes twice a year. So this is evaluating our portfolio for value creation is not like a once every five-year exercise. We're constantly doing it. And I think I'd tell you if we see an opportunity, we've demonstrated that we can act upon it. So right now, my focus here is I'm never going to make a long-term strategic decision based on kind of near-term challenges. Obviously, Nutrition is going through some near-term challenges and going through some transition and recovery phase, and that's what my focus is on -- is on getting our business back to a growth rate that we had seen over the last kind of four or five years. But the idea of constantly evaluating the portfolio that is something that we do for all businesses in the company and we do it on a pretty disciplined basis.
所以現在有很多工作正在進行,但團隊的專注度非常高。我認為這是一支相當有韌性的團隊,Travis,而且表現得相當不錯——至少已經證明在關鍵時刻面對這些挑戰時,他們能很快反彈。所以就目前而言,我會說進度在軌道上,早期跡象令人鼓舞,但仍有工作要做。就投資組合而言。聽著,我喜歡我們商業模式的多元性,而這種多元性不僅是跨業務部門,也跨產品。它體現在我們的地理分布多元、客戶基礎多元、不同的支付方類型,以及不同的創新週期。我們不希望公司過度依賴1到2個產品,讓公司被那樣的結構所驅動。我認為這種多元性確實讓我們對全球醫療保健體系有一個相當獨特的視角。話雖如此,Travis,我們一直在檢視我們的投資組合,我們一直在看市場是否仍具吸引力?我們的競爭地位如何?以便我們能判斷:要擴張、要維持?還是可能要縮減?我們與管理層持續進行這項工作,並且至少每年與董事會做一次,有時一年兩次。所以,為了創造價值而評估投資組合並不是每五年才做一次的活動。我們一直在做。我想我也會告訴你,如果我們看到機會,我們已經證明我們能採取行動。所以現在,我的重點是:我永遠不會因為短期挑戰就做出長期的策略決策。顯然,營養業務正經歷一些短期挑戰,正處於轉型與復甦階段,而我的重點——就是讓我們的業務回到過去大約四、五年所見到的成長率。但持續評估投資組合這件事,是我們對公司所有業務都會做的,而且我們是以相當嚴謹的方式在做。
Travis Steed - Analyst
Travis Steed - Analyst
Great. Thanks a lot.
很好。非常感謝。
Operator
Operator
Joanne Wuensch, Citi.
Joanne Wuensch,花旗。
Joanne Wuensch - Analyst
Joanne Wuensch - Analyst
Good morning, and thank you for taking the question. I'm sort of surprised for 50 minutes into this and no one's asked about macro issues. So I'm going to go there. I'm curious what you're seeing in terms of the potential impacts for the conflict in the Middle East on your business on oil and resin costs, but also just a big picture of what you're seeing in terms of patient volumes and reimbursement and outside of your comments under respiratory snow days and things like that. Thank you.
早安,謝謝讓我提問。我有點驚訝,這場進行了50分鐘,竟然還沒有人問到總體環境議題。所以我就來問這個。我想了解你們看到中東衝突對你們業務可能造成的影響,包括油價與樹脂成本,但也想從更宏觀的角度了解你們在病患量、給付/報銷方面看到的情況;除了你先前提到的呼吸道業務遇到下雪天等因素的評論之外。謝謝。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Sure. Listen, we're -- the way Abbott has been built, it's been built to withstand these kinds of events. And our discipline here is to ensure that we try and get ahead of it. As it relates to oil costs, I mean I think that's an impact that it's too early to tell. We're not seeing any of that in our cost right now.
當然。聽著——Abbott的建構方式,就是為了能承受這類事件。我們在這裡的紀律,是確保我們盡量提前因應。就油價成本而言,我的意思是,我認為現在要判斷其影響還太早。我們目前在成本端還沒有看到任何影響。
We're not seeing freight rates increase from our suppliers right now. But we're monitoring it, and we have a whole team that monitors and stays close to it. I think one of the things that we do to stay ahead of this, Joanne, is that each one of our business has dedicated teams Monday through Friday, 08:00 a.m. to 06:00 p.m., what they do is they work on gross margin improvement, what are ways that we can do to be able to anticipate cost shocks, to look at ways that we can be more efficient, more effective, look at ways at how we can negotiate with our suppliers.
我們目前也沒有看到供應商端的運費費率上升。但我們正在監控,而且我們有一整個團隊負責監測並緊密追蹤。我認為我們用來提前因應的一件事,Joanne,是我們每一個事業部都有專責團隊,週一到週五、上午08:00到下午06:00,他們所做的就是推動毛利率改善:有哪些方法可以讓我們預先因應成本衝擊、找出更有效率與更有效能的作法、以及如何與供應商談判。
And so I don't -- I look at the cost element of the conflict right now, it's too early to tell, but I'm not saying that I think that there is a big impact because I think that we've got teams in place that are working hard to kind of mitigate. The impact that we saw in Q1 was very minimal, Joanne, but I wouldn't call it a demand impact. I would call it more of a getting product into the region kind of impact. As you can imagine, shipping lanes became -- everybody wanted kind of spots on planes and all different types of supply and transport methodology. So that's just something that we got to kind of stay ahead of. One of the things -- the reason we felt a little bit of impact is what we run pretty efficiently with our inventory.
因此,就目前衝突的成本面而言,我認為還太早下定論,但我並不是說我認為會有很大的影響,因為我認為我們已經有團隊在努力做緩解。第一季我們看到的影響非常小,Joanne,但我不會把它稱為需求面的影響;我會把它稱為把產品送進該地區的影響。你可以想像,航運路線變得——大家都想在飛機上搶到艙位,以及各種不同的供應與運輸方式。所以這是我們必須提前掌握的事情。我們之所以感受到一點影響,其中一個原因是我們的庫存運作相當有效率。
So now we need to make sure that we've got more inventory, at least in our affiliates that we have warehouses in the areas, so that we have enough product that so we don't have any kind of back orders. But I didn't see drop-off or demand or reimbursement challenges or issues as a result of the conflict.
所以現在我們需要確保至少在我們於當地設有倉庫的子公司/分支機構那邊有更多庫存,讓我們有足夠的產品,避免出現任何缺貨待交(back orders)。但我沒有看到因衝突而導致的需求下滑,或給付/報銷方面的挑戰或問題。
For us, it was more just ensuring that we could get product into the area. So -- and we're highly focused on that. But as you can imagine, the teams that Abbott has in this region, Joanne. I mean they've -- unfortunately, have been through a lot and seen a lot. And I give them a lot of credit because while we focus on kind of growing the business and driving the business. They've got to do that under some very, very tough challenges. So I give a lot of kudos to the work that they've been doing.
對我們而言,更多是確保我們能把產品送進該地區。所以——我們對此高度專注。但你可以想像,Abbott在這個地區的團隊,Joanne。我的意思是,他們——不幸地——經歷過很多、也見過很多。我非常肯定他們,因為當我們專注於成長業務、推動業務的同時,他們必須在非常、非常艱難的挑戰下完成這些工作。所以我對他們所做的工作給予高度讚賞。
Operator
Operator
Josh Jennings, TD Cowen.
Josh Jennings,TD Cowen。
Joshua Jennings - Analyst
Joshua Jennings - Analyst
Hi, good morning. Thanks for taking the questions. Robert, I'm hoping to get some more details on the EP franchise and the Volt launch internationally and now in the US. Internationally, any quantification of how Volt is impacting share recapture in the ablation catheter segment, for the US just with the early approval of -- I guess, Volt 2.0. Any updates just in terms of the timing or just how your team is going to move forward into a full launch this year and then overall, maybe just help us think about Abbott's updated views on just EP market growth volumes, pricing, if you would. Thanks so much.
嗨,早安。謝謝讓我提問。Robert,我希望能再多了解一些關於EP產品線,以及Volt在國際市場、以及現在在美國的上市情況。國際市場方面,能否量化一下Volt在消融導管(ablation catheter)細分市場中,對於市占回收的影響?美國方面,隨著——我想是Volt 2.0——的早期核准,能否更新一下時程,或你們團隊今年將如何推進到全面上市?另外,整體而言,也請幫我們理解Abbott對EP市場成長的最新看法,包括量(volumes)、價格(pricing)等。非常感謝。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Yeah, sure. Well, that's 55 minutes with that -- with the first EP question. So listen, I think the team has done an incredible job over these past years here of driving double-digit growth during a window where we didn't have PFA, that window is now closed. So obviously, we naturally have expectations and outlooks here that are on the rise.
好的,當然。嗯,這已經55分鐘了——才出現第一個EP問題。聽著,我認為團隊在過去這些年做得非常出色:在我們還沒有PFA的那段期間,仍然推動了兩位數成長;而那個窗口期現在已經結束了。所以很顯然,我們對未來的期待與展望自然也在上升。
The US launch of Volt and the European launch of TactiFlex Duo are on the way. And both these launches are in what we call a limited market release phase. We do that with all of our products. It's just part of our -- it's part of our process, whether it's in diagnostics. What we want to do is before we go to full blown, we believe there's an intermediate step between what I would believe to be a little bit more of a controlled environment or a clinical trial before going full blown. So -- and that helps us. It helps us understand resourcing. It helps us understand positioning. It helps us, quite frankly, uncover insights that you might not get during a clinical trial. The feedback we're getting from both these products is extremely favorable and positive and very much aligns to least our expectation that we did when we were building this portfolio two years ago. Remember, a lot of questions of, hey, we were late. And we said, okay, we realized we're not first, but we want to take advantage of of our mapping systems and develop what we believe was going to be an upgrade to the first generation. I think we're seeing that with Volt.
Volt在美國的上市,以及TactiFlex Duo在歐洲的上市,都正在推進中。而這兩個上市目前都處於我們所稱的「有限市場釋出」(limited market release)階段。我們對所有產品都會這麼做。這只是我們流程的一部分,不論是在診斷業務也是如此。我們想做的是:在全面推開之前,我們相信在我所認為的較受控環境或臨床試驗,與全面推開之間,存在一個中間步驟。所以——這對我們有幫助。它幫助我們了解資源配置;幫助我們了解市場定位;也坦白說,幫助我們挖掘一些你在臨床試驗期間可能得不到的洞見。我們從這兩個產品收到的回饋都非常有利、非常正面,也非常符合——至少——我們兩年前建立這個產品組合時的預期。記得當時有很多問題在問:嘿,我們落後了。我們說,好,我們知道我們不是第一個,但我們想利用我們的mapping系統,並開發我們認為能對第一代產品做出升級的方案。我想我們在Volt上正看到這一點。
I think like the conscious sedation aspect of Volt is extremely valuable, more so now as in the US but even internationally. And that's something that's specific to Volt in terms of how we design that. And I think if you paid attention to the European Heart Rhythm meeting that occurred last week.
我認為Volt的「清醒鎮靜」(conscious sedation)特性非常有價值,現在在美國尤其如此,但在國際上也是。而這在設計上是Volt所特有的。我想如果你有關注上週舉行的歐洲心律失常(Heart Rhythm)會議的話。
I think you saw also, albeit preliminary and may be small, but this idea that the lesions that Volt creates are more durable and I think ultimately, that repositions, I think, or at least balances the discussion on the EP market to be, yes, we want more efficiency, we want more speed in these procedures because you've got so many patients that you can treat but we want to also figure out how to do better outcomes and how to improve patient outcomes. And I think that that's what we're believe that Volt can do is to actually deliver on the promise of speed, efficiency, but also an ability to deliver better outcomes. I think the TactiFlex feedback that we're seeing, Josh, is very positive also easy to use, very fast lesion creations. This is on the TactiFlex chassis. So there's a lot of experience with that catheter, pretty seamless switch between RF to PFA. So all very positive. So I think the combination of that great feedback and now us starting to move to broaden the launch is going to give us a lot of confidence here in the growth rate to accelerate and I think that includes growing faster than the market by the exit of this year. To your comment, I mean, I know there's a lot of debate about what is it? Is it 15? Is it 20? we think the market is going to be in the mid- to high teens. We're shooting to do better than that. So I think there's an acceleration here. So the near-term outlook, I think, for the business looks really strong. But I think more importantly here, Josh, is I like our position long term also. You've got two new PFA catheters, you've got a new ice catheter, you got a new introducer. We're constantly making upgrades -- annual upgrades to our mapping system. You have the mapping infrastructure in place with the clinical specialists a highly valuable asset to our customers to have that. And then on top of that, we're now going to be adding a second generation LAA device to this group I think that no company in this space has got the kind of portfolio that we have and the completeness of the portfolio that we have and the experience and the field teams, et cetera.
我想你也看到了,雖然仍屬初步、規模可能不大,但這個觀點是 Volt 所形成的病灶更為持久;我認為最終這會重新定位——我想,或至少能平衡——對 EP 市場的討論:是的,我們希望這些手術更有效率、更快速,因為有太多病患需要治療;但我們也希望找出如何帶來更好的結果、如何改善病患預後。我認為我們相信 Volt 能做到的,就是兌現速度與效率的承諾,同時也具備帶來更佳結果的能力。我認為我們看到的 TactiFlex 回饋也非常正面,Josh——易於使用、病灶形成非常快速。這是在 TactiFlex 平台上,所以大家對這支導管有很多使用經驗,從 RF 切換到 PFA 幾乎無縫銜接,一切都非常正面。因此,我認為這些很棒的回饋,再加上我們現在開始擴大上市範圍,將讓我們對成長率加速更有信心;我認為這也包括在今年年底前的退出時點,成長速度快於市場。回到你的評論,我的意思是,我知道大家對到底是多少有很多爭論:是 15?是 20?我們認為市場會在十幾%的中段到高段,我們的目標是做得比這更好。所以我認為這裡會有加速。因此,我認為短期的業務展望看起來非常強勁。但更重要的是,Josh,我也喜歡我們的長期位置。你有兩款新的 PFA 導管、一款新的 ICE 導管、一個新的導入器。我們持續對我們的 mapping 系統做升級——每年升級。你也有 mapping 的基礎設施與臨床專員,對客戶而言這是非常有價值的資產。除此之外,我們現在還要在這個組合中加入第二代 LAA 裝置;我認為在這個領域,沒有任何公司擁有像我們這樣的產品組合、如此完整的產品組合,以及經驗與前線團隊等等。
So -- and I know this is not a product that specifically falls into EP as a reportable segment, but we have a lot of VPs that are also using devices, pacemakers, ICDs and then you add on our leadless technology, which is very fast growing. I think we have a very, very differentiated EP product portfolio. And so I think there are a lot of exciting times in the horizon here for our EP business.
所以——我知道這不是一個明確歸類在 EP、可作為報告分部的產品,但我們也有很多 VPs 同時在使用裝置、心律調節器、ICDs,然後再加上我們成長非常快速的無導線技術。我認為我們擁有非常、非常差異化的 EP 產品組合。因此,我認為我們的 EP 業務在未來將迎來許多令人振奮的時刻。
Mike Comilla - Vice President, Investor Relations
Mike Comilla - Vice President, Investor Relations
Crystal, we'll take one more question, please.
Crystal,我們再接一個問題,謝謝。
Operator
Operator
Marie Thibault, BTIG.
Marie Thibault,BTIG。
Marie Thibault - Analyst
Marie Thibault - Analyst
Good morning. Thanks for squeezing me in. I just want to get a little bit closer to understanding what's going on in the ore Lab business. I think you've called out strength in the US Europe and Latin America, I think we're moving past some of the China VBP headwind. So wondering if you can just characterize the Core Lab trajectory by geography during Q1. Any share gains, any notable product launches, things like that to call out? Thanks for taking the questions.
早安。謝謝讓我插隊提問。我想更貼近地了解 Core Lab 業務目前的狀況。我想你們提到美國、歐洲與拉丁美洲表現強勁,而且我想我們正在走出中國 VBP 的逆風。所以想請你們描述一下第一季 Core Lab 依地區別的走勢:是否有市占提升?是否有值得一提的產品上市?之類的重點?謝謝回答問題。
Robert Ford - Chairman of the Board, Chief Executive Officer
Robert Ford - Chairman of the Board, Chief Executive Officer
Yeah, sure. I think you kind of characterized it well. I mean, I think our sales in China for Core Lab were flat in Q1. If you think about what they were in last year, we were between 50% and 30% down every quarter. So I think the teams here are making good progress. We're lapping obviously some of the price and the volume headwinds. So that's also a contributor there.
好的,當然。我想你的描述大致正確。我的意思是,我們第一季在中國的 Core Lab 銷售是持平的。若回想去年,我們每一季都下滑約 50% 到 30%。所以我認為團隊在這裡取得了不錯的進展。我們顯然正在跨越一些價格與量的逆風基期,所以這也是其中一個貢獻因素。
So I think the market dynamics that we faced kind of, China. I'm cautious to say like it's all lapped because as we know in these VPs, you've got different kind of phases. You've got regionals, you've got nationals and all of that. But I think the impact here is we've got China modeled in at a single-digit decline for the year. Could we do better than that? It seems like the team has done better than that in the first quarter, and I'm hoping they'll be able to do that.
所以我認為我們在中國面對的市場動態——我會謹慎地說,不能說已經完全跨越,因為如同我們所知,在這些 VBP 中,你會有不同的階段:有區域性的、有全國性的等等。但我認為目前的影響是,我們對中國的模型假設是全年呈現個位數下滑。我們能做得比這更好嗎?看起來團隊在第一季確實做得比這更好,我也希望他們能持續做到。
I think if I move to the US I think, as I said in a previous question, I think the US team has done a fantastic job and the growth rates there are all in the high single digits, than they've been like that for some time. So we're clearly having an ability to take -- to renew our contracts at a very high renewal rate, so call it, 90-plus, and share gains are now accelerating. So our win rates, I would call 55 plus. So every business that we're up in new business, we're able to win one out of two.
我想如果轉到美國,如我在前一個問題中所說,我認為美國團隊做得非常出色,那裡的成長率都在高個位數,而且已經維持一段時間了。所以我們顯然有能力以非常高的續約率來更新合約,大約可說是 90% 以上,而市占提升現在也在加速。因此我們的得標率,我會說是 55% 以上。也就是說,每當我們參與新的業務競標時,我們大約能贏下二分之一。
So that's a good trajectory over here. Europe, it's difficult to characterize as one big Europe because as you probably know, you've got different situations between North and South. But in general, that business has been doing mid- to high single digits pretty reliably.
所以這是一個很好的走勢。歐洲方面,很難把它當作一個整體歐洲來描述,因為如你所知,北歐與南歐的情況不同。但總體而言,那個業務一直相當穩定地維持在中到高個位數成長。
So we feel very good about the diagnostic business. It has been performing well all but the impact of VBP in China, and that seems to be lapping. So I expect to be getting -- the full year for our core lab business is kind of in that mid-single-digit growth rate.
所以我們對診斷業務感到非常滿意。除了中國 VBP 的影響之外,它一直表現良好,而那似乎正在跨越基期。因此我預期——我們全年 core lab 業務大致會落在中個位數的成長率。
I was talking to the leader of that business yesterday, they've got a plan and some strategies that probably they could do better than that. But obviously, the second half is higher than that, and it falls into what we've historically been doing.
我昨天和該業務的負責人談過,他們有一個計畫與一些策略,可能可以做得比這更好。但顯然,下半年會高於這個水準,而這也符合我們過去一貫的表現。
And like I said, I think the team has done a very good job there at navigating VBP in China and continue to drive growth in any other parts of the business. So I think that's gone very well. Paying attention for us in China, about 80% of our portfolio has gone through VBP. I think you'll probably hear about new ways of VBP, like a fertility VBP, a cancer VBP.
而且如我所說,我認為團隊在中國因應 VBP、並持續推動業務其他部分的成長方面做得非常好。我認為這進展得很順利。就中國而言,我們約 80% 的產品組合已經經歷過 VBP。我想你們可能也會聽到一些新的 VBP 形式,例如生殖 VBP、癌症 VBP。
And so we have very little share in those segments. So I think I don't want to say we're past the eye of the hurricane here, but it seems like the teams have been able to kind of stabilize China, and then the other businesses continue to perform the way they've historically been performing.
因此我們在那些領域的市占很小。所以我不想說我們已經走過颶風眼,但看起來團隊已經能夠讓中國業務某種程度上穩定下來,而其他業務則持續以其歷史表現的方式運作。
So just before we end the call, I'd like just to reiterate my comments that I've made at the end of my prepared remarks, I remain very confident in our expectation here for an acceleration in growth in the second half. Like I said earlier, we know what the drivers are we know where the accelerations are. We know where areas that we need to improve our execution on and we are just laser highly focused on executing on them. So with that, I'm going to wrap up, and thank you all for joining us today.
所以在我們結束電話會議之前,我想重申我在事先準備講稿結尾所提到的評論:我對我們下半年成長加速的預期仍然非常有信心。如我先前所說,我們知道驅動因素是什麼,我們知道加速點在哪裡。我們也知道哪些領域需要改善執行,而我們正以雷射般的高度專注來落實執行。因此,我就先做個總結,並感謝各位今天加入我們。
Mike Comilla - Vice President, Investor Relations
Mike Comilla - Vice President, Investor Relations
Thank you, operator. Thank you all for your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central Time today on our website at abbott.com. Thank you for joining us today.
謝謝,接線員。也謝謝各位的提問。阿博特的電話會議到此結束。本次電話會議的網路重播將於今天中部時間上午 11:00 之後在我們的網站 abbott.com 提供。感謝各位今天的參與。
Operator
Operator
Thank you. This concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.
謝謝。本日電話會議到此結束。感謝各位的參與。您現在可以掛線。祝各位有美好的一天。